Endonovo Therapeutics annual revenue
2010
2011
2012
2013
2014
2015
2018
2019
2020
2021
2022
2023
2024
Endonovo Therapeutics Revenue Growth & History (ENDV)
Endonovo Therapeutics reported $10,043 in revenue for fiscal 2024, a decrease of 92.84% from the previous fiscal year.
View full Endonovo Therapeutics company overviewEndonovo Therapeutics annual revenue and growth
| Fiscal year | Period ended | Revenue | Change | Growth |
|---|---|---|---|---|
| 2024 | 2024-12-31 | $10,043 | −$130,199 | −92.84% |
| 2023 | 2023-12-31 | $140,242 | $4,887 | +3.61% |
| 2022 | 2022-12-31 | $135,355 | $62,250 | +85.15% |
| 2021 | 2021-12-31 | $73,105 | −$92,691 | −55.91% |
| 2020 | 2020-12-31 | $165,796 | −$144,368 | −46.55% |
| 2019 | 2019-12-31 | $310,164 | $226,901 | +272.51% |
| 2018 | 2018-12-31 | $83,263 | — | — |
| 2015 | 2015-12-31 | $4,265 | −$19,927 | −82.37% |
| 2014 | 2014-12-31 | $24,192 | $1,296 | +5.66% |
| 2013 | 2013-12-31 | $22,896 | −$7,685 | −25.13% |
| 2012 | 2012-12-31 | $30,581 | −$14,963 | −32.85% |
| 2011 | 2011-12-31 | $45,544 | −$5,655 | −11.05% |
| 2010 | 2010-12-31 | $51,199 | — | — |
Endonovo Therapeutics quarterly revenue
Q1.11
Q1.12
Q2.12
Q3.12
Q4.12
Q1.13
Q2.13
Q3.13
Q4.13
Q1.14
Q2.14
Q3.14
Q4.14
Q1.15
Q2.15
Q3.15
Q4.15
Q4.15
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.24
Q1.25
Q2.25
| Fiscal quarter | Period ended | Revenue | Change | YoY growth |
|---|---|---|---|---|
| Q2 2025 | 2025-06-30 | $0 | — | — |
| Q1 2025 | 2025-03-31 | $0 | — | — |
| Q4 2024 | 2024-12-31 | $0 | — | — |
| Q3 2023 | 2023-09-30 | $1,520 | −$9,440 | −86.13% |
| Q2 2023 | 2023-06-30 | $45,200 | $44,550 | +6853.85% |
| Q1 2023 | 2023-03-31 | $87,540 | $85,258 | +3736.11% |
| Q4 2022 | 2022-12-31 | $121,463 | $121,147 | +38337.66% |
| Q3 2022 | 2022-09-30 | $10,960 | $3,170 | +40.69% |
| Q2 2022 | 2022-06-30 | $650 | −$29,634 | −97.85% |
| Q1 2022 | 2022-03-31 | $2,282 | −$32,433 | −93.43% |
| Q4 2021 | 2021-12-31 | $316 | −$11,184 | −97.25% |
| Q3 2021 | 2021-09-30 | $7,790 | −$32,190 | −80.52% |
| Q2 2021 | 2021-06-30 | $30,284 | −$14,347 | −32.15% |
| Q1 2021 | 2021-03-31 | $34,715 | −$34,970 | −50.18% |
| Q4 2020 | 2020-12-31 | $11,500 | −$136,944 | −92.25% |
| Q3 2020 | 2020-09-30 | $39,980 | −$14,059 | −26.02% |
| Q2 2020 | 2020-06-30 | $44,631 | −$18,098 | −28.85% |
| Q1 2020 | 2020-03-31 | $69,685 | $24,733 | +55.02% |
| Q4 2019 | 2019-12-31 | $148,444 | $106,313 | +252.34% |
| Q3 2019 | 2019-09-30 | $54,039 | $32,733 | +153.63% |
| Q2 2019 | 2019-06-30 | $62,729 | $49,875 | +388.01% |
| Q1 2019 | 2019-03-31 | $44,952 | $37,980 | +544.75% |
| Q4 2018 | 2018-12-31 | $42,131 | — | — |
| Q3 2018 | 2018-09-30 | $21,306 | — | — |
| Q2 2018 | 2018-06-30 | $12,854 | — | — |
| Q1 2018 | 2018-03-31 | $6,972 | — | — |
| Q4 2015 | 2016-03-31 | $0 | −$2,745 | −100.00% |
| Q4 2015 | 2015-12-31 | $0 | $30,629 | +100.00% |
| Q3 2015 | 2015-09-30 | −$400 | −$21,040 | −101.94% |
| Q2 2015 | 2015-06-30 | $1,920 | −$14,502 | −88.31% |
| Q1 2015 | 2015-03-31 | $2,745 | −$15,014 | −84.54% |
| Q4 2014 | 2014-12-31 | −$30,629 | −$53,525 | −233.77% |
| Q3 2014 | 2014-09-30 | $20,640 | $20,640 | — |
| Q2 2014 | 2014-06-30 | $16,422 | $16,422 | — |
| Q1 2014 | 2014-03-31 | $17,759 | $17,759 | — |
| Q4 2013 | 2013-12-31 | $22,896 | $9,240 | +67.66% |
| Q3 2013 | 2013-09-30 | $0 | −$7,161 | −100.00% |
| Q2 2013 | 2013-06-30 | $0 | −$8,091 | −100.00% |
| Q1 2013 | 2013-03-31 | $0 | −$1,673 | −100.00% |
| Q4 2012 | 2012-12-31 | $13,656 | — | — |
| Q3 2012 | 2012-09-30 | $7,161 | — | — |
| Q2 2012 | 2012-06-30 | $8,091 | — | — |
| Q1 2012 | 2012-03-31 | $1,673 | $1,673 | — |
| Q1 2011 | 2011-03-31 | $0 | — | — |
Endonovo Therapeutics revenue growth trends
Over the last five reported fiscal years, revenue declined from $310,164 to $10,043, a compound annual decline of 49.64%. Endonovo Therapeutics's latest reported quarter, Q2 2025, generated $0 in revenue.
About the data
What revenue means
Revenue is the top-line amount a company reports from selling goods and services before expenses are deducted. Fiscal periods can differ from calendar years, so each table includes the exact period end date.
Financial data
Standardized company financials
TickerStat standardizes company financial facts for consistent comparison. Derived growth rates use the displayed values and are not guidance or forecasts.
Review Endonovo Therapeutics source filings ↗